Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Helix BioPharma's Total Liabilities for the quarter that ended in Apr. 2026 was $4.87 Mil. Helix BioPharma's Total Assets for the quarter that ended in Apr. 2026 was $15.55 Mil.
Therefore, Helix BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Apr. 2026 was 0.31.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Helix BioPharma Liabilities-to-Assets Related Terms
Helix BioPharma Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBPCF vs VRTX, REGN, ALNY: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Helix BioPharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Helix BioPharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Jul. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a Liabilities-to-Assets of 0.31 as of Apr. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's Liabilities-to-Assets too high?
Helix BioPharma's current Liabilities-to-Assets is 0.31. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Liabilities-to-Assets compare to VRTX and REGN?
Helix BioPharma's Liabilities-to-Assets of 0.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current Liabilities-to-Assets is 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Liabilities-to-Assets of 0.31. The current Liabilities-to-Assets is 0.31. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Liabilities-to-Assets is 0.31 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
